Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DexComDXCM +11.95%92 Equity-to-Asset is 0.41 as of Jun. 2026, which is 2% above its 10-year median of 0.40. GuruFocus rates DXCM with a GF Score™ of 92/100 and a GF Value™ of $100.88 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, DexCom ranks worse than 72.18% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. DexCom's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $2,621 Mil. DexCom's Total Assets for the quarter that ended in Jun. 2026 was $6,455 Mil.
Therefore, DexCom's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.41.
The historical rank and industry rank for DexCom's Equity-to-Asset or its related term are showing as below:
DXCM'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31 Med: 0.4 Max: 0.72
Current: 0.41
During the past 13 years, the highest Equity to Asset Ratio of DexCom was 0.72. The lowest was 0.31. And the median was 0.40.
DXCM's Equity-to-Asset is ranked worse than 72.18% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs DXCM: 0.41
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
DexCom Equity-to-Asset Related Terms
DexCom Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for DexCom's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DXCM vs GEHC, STE, ZBH: Equity-to-Asset Comparison
For the Medical Devices subindustry, DexCom's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where DexCom's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
DexCom's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexCom (DXCM) has a Equity-to-Asset of 0.41 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on DexCom and its competitors. This is near median its historical median of 0.40. Over the past decade, DexCom's Equity-to-Asset has ranged from 0.31 to 0.72. According to the industry distribution chart, DexCom ranks #615 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 72.2%.
Is DexCom's Equity-to-Asset too high?
DexCom's current Equity-to-Asset of 0.41 is near median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 0.72. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. DexCom's value of 0.41 is 36.4% below this industry median. Based on the distribution chart, DexCom ranks #615 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, DexCom has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Equity-to-Asset compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #615 out of 852 companies for Equity-to-Asset. This places DexCom in the lower half of its industry. The industry median Equity-to-Asset is 0.65. DexCom's value of 0.41 is 36.4% below this benchmark. Historically, DexCom's own Equity-to-Asset has ranged from 0.31 to 0.72 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 0.65, DexCom has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexCom's current Equity-to-Asset of 0.41 is 36.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on DexCom and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current Equity-to-Asset is 0.41, which is near median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Modestly Undervalued. The stock's GF Value™ is $100.88, compared to a current price of $83.45 — trading 17.3% below its estimated fair value. The current Equity-to-Asset is 0.41, which is near median its 10-year median of 0.40 and 36.4% below the Medical Devices & Instruments industry median of 0.65. DexCom's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For DexCom (DXCM), the current Equity-to-Asset is 0.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of $83.45 is trading 17.3% below its estimated GF Value™ of $100.88.
GuruFocus considers DexCom to be Modestly Undervalued.
Key valuation signals for DXCM:
Equity-to-Asset: 0.41 (near median its 10-year median of 0.40)
GF Value™: $100.88 vs. price of $83.45 (17.3% below fair value)
Industry Position: 36.4% below the Medical Devices & Instruments median (#615 of 852)
No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
92GF Score
Get the complete analysis for DXCM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DXCM has been successfully added to your 
